Literature DB >> 28993335

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.

Sergio Serrano-Villar1, Giorgia Caruana2, Alexander Zlotnik3, José A Pérez-Molina4, Santiago Moreno4.   

Abstract

A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8+ T-cell decline.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD4/CD8 ratio; HIV; T cells; T-cell activation; antiretroviral therapy; efavirenz; maraviroc

Mesh：

Substances：

Year:  2017        PMID： 28993335      PMCID： PMC5700350          DOI： 10.1128/AAC.01763-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  HIV infection, inflammation, immunosenescence, and aging.

Authors:  Steven G Deeks
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

2.  Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.

Authors:  Corrilynn O Hileman; Bruce Kinley; Valeska Scharen-Guivel; Kathy Melbourne; Javier Szwarcberg; Janet Robinson; Michael M Lederman; Grace A Mccomsey
Journal:  J Infect Dis       Date:  2015-01-12       Impact factor: 5.226

3.  CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

Authors:  Cristina Mussini; Patrizia Lorenzini; Alessandro Cozzi-Lepri; Giuseppe Lapadula; Giulia Marchetti; Emanuele Nicastri; Antonella Cingolani; Miriam Lichtner; Andrea Antinori; Andrea Gori; Antonella d'Arminio Monforte
Journal:  Lancet HIV       Date:  2015-02-06       Impact factor: 12.767

4.  Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.

Authors:  Connie J Kim; Rodney Rousseau; Sanja Huibner; Colin Kovacs; Erika Benko; Kamnoosh Shahabi; Gabor Kandel; Mario Ostrowski; Rupert Kaul
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

5.  Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.

Authors:  Sine Reker Hadrup; Jan Strindhall; Tania Køllgaard; Tina Seremet; Boo Johansson; Graham Pawelec; Per thor Straten; Anders Wikby
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

6.  Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Authors:  Nicholas Funderburg; Magdalena Kalinowska; James Eason; James Goodrich; Jayvant Heera; Howard Mayer; Natasa Rajicic; Hernan Valdez; Michael M Lederman
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

7.  Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.

Authors:  Ellen S Chan; Alan L Landay; Todd T Brown; Heather J Ribaudo; Paria Mirmonsef; Igho Ofotokun; M Neale Weitzmann; Jeffrey Martinson; Karin L Klingman; Joseph J Eron; Carl J Fichtenbaum; Jill Plants; Babafemi O Taiwo
Journal:  AIDS       Date:  2016-08-24       Impact factor: 4.177

8.  Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.

Authors:  Thomas M Gates; Lucette A Cysique; Krista J Siefried; Joga Chaganti; Kirsten J Moffat; Bruce J Brew
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

9.  Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio.

Authors:  Sergio Serrano-Villar; María Jesús Pérez-Elías; Fernando Dronda; José Luis Casado; Ana Moreno; Ana Royuela; José Antonio Pérez-Molina; Talia Sainz; Enrique Navas; José Manuel Hermida; Carmen Quereda; Santiago Moreno
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

10.  HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.

Authors:  Sergio Serrano-Villar; Talia Sainz; Sulggi A Lee; Peter W Hunt; Elizabeth Sinclair; Barbara L Shacklett; April L Ferre; Timothy L Hayes; Ma Somsouk; Priscilla Y Hsue; Mark L Van Natta; Curtis L Meinert; Michael M Lederman; Hiroyu Hatano; Vivek Jain; Yong Huang; Frederick M Hecht; Jeffrey N Martin; Joseph M McCune; Santiago Moreno; Steven G Deeks
Journal:  PLoS Pathog       Date:  2014-05-15       Impact factor: 6.823
View more
  4 in total

1.  Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort.

Authors:  Sabina Herrera; Borja M Fernandez-Felix; Peter W Hunt; Steven G Deeks; Talía Sainz; Sonya L Heath; Chad J Achenbach; Benigno Rodríguez; Christopher Mathews; Katerina Christopoulos; Kenneth Mayer; Sonia Napravnik; Santiago Moreno; Sergio Serrano-Villar
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

Review 2.  CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.

Authors:  Fedora Grande; Maria Antonietta Occhiuzzi; Bruno Rizzuti; Giuseppina Ioele; Michele De Luca; Paola Tucci; Valentina Svicher; Stefano Aquaro; Antonio Garofalo
Journal:  Molecules       Date:  2019-02-02       Impact factor: 4.411

3.  Association Between CD4/CD8 Ratio Recovery and Chronic Kidney Disease Among Human Immunodeficiency Virus-Infected Patients Receiving Antiretroviral Therapy: A 17-Year Observational Cohort Study.

Authors:  Fengxiang Qin; Qing Lv; Wen Hong; Di Wei; Kui Huang; Ke Lan; Rongfeng Chen; Jie Liu; Bingyu Liang; Huayue Liang; Hao Liang; Shanfang Qin; Li Ye; Junjun Jiang
Journal:  Front Microbiol       Date:  2022-02-10       Impact factor: 5.640

4.  Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4+:CD8+ T-cell ratio in treated HIV-1 infection.

Authors:  Inês T Freitas; Willard Tinago; Hirofumi Sawa; Julie McAndrews; Brenda Doak; Charlotte Prior-Fuller; Gerard Sheehan; John S Lambert; Eavan Muldoon; Aoife G Cotter; William W Hall; Patrick W G Mallon; Michael J Carr
Journal:  AIDS Res Ther       Date:  2020-04-15       Impact factor: 2.250
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.